TY - JOUR
T1 - Kinetics of Ischaemia Modified Albumin During Ongoing Severe Myocardial Ischaemia
AU - Hjortshøj, Søren
AU - Dethlefsen, Claus
AU - Kristensen, Søren Risom
AU - Ravkilde, Jan
PY - 2009
Y1 - 2009
N2 - BACKGROUND: Release kinetics of Ischaemia Modified Albumin (IMA) have not been described in detail and never in ongoing acute coronary syndrome. We compared IMA kinetics with early necrosis biomarkers during ST-segment elevation myocardial infarction (STEMI) and in different populations with ischaemic heart disease and healthy subjects. METHODS: We investigated 1. patients with ongoing STEMI (n=25), 2. patients with Non-ST segment elevation MI (n=5), 3. patients with stable angina (n=5), 4. healthy subjects (n=5). Groups 1-3 underwent percutaneous coronary intervention (PCI). Fourteen blood samples were collected, of which 11 were obtained during the first 24 hours following PCI. Samples were analyzed for IMA, cardiac troponin T, CKMBmass, myoglobin, and heart-type fatty acid binding protein. RESULTS: In the STEMI group, mean IMA increased to 16% above upper limit of normal, peaking 40 minutes after PCI, and nearly normalizing within 2.5 hours. Relative concentrations of IMA were low compared to other cardiac biomarkers. In all other groups, changes were non-significant. CONCLUSIONS: IMA is a marker of cardiac ischaemia with rapid clearance and a narrow diagnostic time window that may decrease NPV and clinical usefulness due to its dependency of short symptoms duration. Sensitivity of the assay was low compared to other markers.
AB - BACKGROUND: Release kinetics of Ischaemia Modified Albumin (IMA) have not been described in detail and never in ongoing acute coronary syndrome. We compared IMA kinetics with early necrosis biomarkers during ST-segment elevation myocardial infarction (STEMI) and in different populations with ischaemic heart disease and healthy subjects. METHODS: We investigated 1. patients with ongoing STEMI (n=25), 2. patients with Non-ST segment elevation MI (n=5), 3. patients with stable angina (n=5), 4. healthy subjects (n=5). Groups 1-3 underwent percutaneous coronary intervention (PCI). Fourteen blood samples were collected, of which 11 were obtained during the first 24 hours following PCI. Samples were analyzed for IMA, cardiac troponin T, CKMBmass, myoglobin, and heart-type fatty acid binding protein. RESULTS: In the STEMI group, mean IMA increased to 16% above upper limit of normal, peaking 40 minutes after PCI, and nearly normalizing within 2.5 hours. Relative concentrations of IMA were low compared to other cardiac biomarkers. In all other groups, changes were non-significant. CONCLUSIONS: IMA is a marker of cardiac ischaemia with rapid clearance and a narrow diagnostic time window that may decrease NPV and clinical usefulness due to its dependency of short symptoms duration. Sensitivity of the assay was low compared to other markers.
U2 - 10.1016/j.cca.2009.01.033
DO - 10.1016/j.cca.2009.01.033
M3 - Journal article
VL - 403
SP - 114
EP - 120
JO - Clinica chimica acta; international journal of clinical chemistry
JF - Clinica chimica acta; international journal of clinical chemistry
ER -